DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance

Information source: Centers for Disease Control and Prevention
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV; Malaria; Diarrhea; Pneumonia; Opportunistic Infections

Intervention: Cotrimoxazole (trimethoprim sulfamethoxazole) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Centers for Disease Control and Prevention

Official(s) and/or principal investigator(s):
Mary J Hamel, M.D., Principal Investigator, Affiliation: Centers for Disease Control and Prevention


At least three studies in sub-Saharan Africa have demonstrated a decrease in morbidity or mortality among HIV-infected adults who took daily cotrimoxazole (trimethoprim sulfamethoxazole) [CTX] prophylaxis. Because of the demonstrated beneficial effect, high tolerability and low cost of CTX, the United Nations Programme on HIV/AIDS (UNAIDS) recommends that HIV-infected persons with symptomatic HIV or depressed CD4 counts receive daily CTX. The effect of this recommendation on subsequent development of antimicrobial resistance to antifolates among important pathogens needs to be evaluated. The investigators measured the change in the prevalence of markers of antifolate resistance among P. falciparum, and the change in the prevalence of CTX resistance among S. pneumoniae, and E. coli in HIV-infected individuals receiving CTX daily prophylaxis. In addition, the investigators measured the change in the prevalence of naso-pharyngeal or oro-pharyngeal carriage of CTX resistant S. pneumoniae among children living in households where an HIV-infected adult was receiving CTX daily prophylaxis.

Clinical Details

Official title: An Evaluation of the Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on the Development of Antifolate Resistance Among Plasmodium Falciparum, Streptococcus Pneumoniae, and Escherichia Coli

Study design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training

Primary outcome:

Change in Plasmodium falciparum molecular markers of antifolate resistance before and while taking daily CTX

Change in nasopharyngeal pneumococcal resistance before and while taking daily CTX, and among children living in households where adults are taking daily CTX

Change in commensal E. coli resistance before and while taking daily CTX

Secondary outcome:

To measure CTX-resistance among Salmonella and other enteric bacterial pathogens in patients with diarrhea in the study area

To assess the efficacy of sulfadoxine-pyrimethamine (SP) treatment of breakthrough P. falciparum parasitemia and clinical malaria among HIV-infected persons taking daily CTX prophylaxis

To measure sulfa metabolite levels in HIV-infected persons receiving daily CTX who develop a drug reaction, to determine if differing rates of metabolism contribute to the development of adverse reactions

To assess the effect of daily CTX prophylaxis on the etiology of diarrheal diseases in HIV-infected persons

To evaluate the serotype distribution of and immune response to colonizing pneumococci

To assess the cause of diarrheal diseases among HIV-infected persons

To measure the change in quality of life indicators among clients receiving daily CTX

Detailed description: We conducted this study in Kisumu, Kenya where HIV prevalence is high and malaria is highly endemic. HIV infected and uninfected adults were assigned to receive daily CTX if CD4 cell count was <350, or daily multivitamin if CD4 cell count was >= 350 or if the client was HIV negative. All clients were then followed for a total of 6 months. At specified scheduled and sick visits, clients received a physical exam, blood smears, nasopharyngeal swabs and stool samples or rectal swabs. Samples collected at baseline and during follow-up were used to measure the change in CTX resistance among P. falciparum parasites, pneumococcus isolates, and commensal E. coli.


Minimum age: 15 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: Clients presenting to the CRC HIV counseling and testing site in Kisumu were eligible for the study if they met the following inclusion criteria:

- 15 years of age or older

- Able to make all follow-up visits (i. e. do not plan to leave Kisumu during the next 6

months, are not homebound)

- Able to understand and give informed consent.

Exclusion Criteria: Clients were not eligible for the study if they met any of the following exclusion criteria:

- Known allergic reaction to sulfa medications (i. e. CTX, sulfadoxine- pyrimethamine)

- Women in their first trimester of pregnancy or planning to become pregnant in the

next 6 months

- Clients taking daily antibiotics for treatment of a chronic illness; or prophylaxis,

excluding tuberculosis treatment.

Locations and Contacts

CDC KEMRI Research Institute, Kisumu, Kenya
Additional Information

Starting date: February 2002
Last updated: December 12, 2005

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017